WebNational Center for Biotechnology Information WebWe retrospectively identified adults over 18 years with newly diagnosed WHO-defined AML/high grade myeloid neoplasms (>10% blasts) who received high intensity induction chemotherapy (cladribine, cytarabine, mitoxantrone, and G-CSF, also known as CLAG-M or GCLAM) between 5/1/2014 and 12/31/2024. Patients with variations to the CLAG-M …
Halpern (@Aralhalpern) / Twitter
WebMay 22, 2024 · This phase I/II trial studies the side effects and best dosing frequency of gemtuzumab ozogamicin when given in combination with granulocyte colony stimulating factor (G-CSF), cladribine, cytarabine and mitoxantrone (GCLAM) and to see how well they work in treating participants with acute myeloid leukemia or high-grade myeloid tumors … WebNov 1, 2024 · Our data indicate GCLAM with mitoxantrone at 18 mg/m2/day is safe and induces high-quality remissions in adults with newly-diagnosed AML. ... Anna B. … the perfume shop oldham
(PDF) Phase 1/2 Trial of GCLAM with Dose-Escalated
WebMar 6, 2024 · GCLAM therapy shows promise for relapsed/refractory AML. Publish date: March 6, 2024. By Sharon Worcester ... WebOutcomes with "7 + 3" are often unsatisfactory in acute myeloid leukemia (AML). Trials demonstrating improved outcomes with high-dose cytarabine, addition of cladribine, or escalated anthracycline doses prompted a phase 1/2 study (NCT02044796) of G-CSF, cladribine, high-dose cytarabine, and dose-escalated mitoxantrone (GCLAM) in adults … WebPhase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Halpern, Anna B ; Othus, Megan ; Huebner, Emily M ; Scott, Bart L ; Becker, Pamela S ; Percival, Mary-Elizabeth M ; Hendrie, Paul C ; ... the perfume shop oxford